Sapreme Technologies is developing proprietary endosomal escape technology that enhances the intracellular delivery of large RNA molecules, such as ASOs and siRNAs, to target tissues including the liver, muscle, and brain. This technology addresses the inefficiency of less than 1% of next-generation therapeutics crossing cellular barriers, thereby improving treatment options for genetically driven diseases.
Funding
$17.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Delivery of large RNA molecules, such as antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs), to intracellular targets is inefficient, with less than 1% crossing cellular barriers. This limits the effectiveness of next-generation therapeutics for genetically driven diseases.
Solution
Sapreme Technologies is developing a proprietary endosomal escape technology platform (SPT) to enhance the intracellular delivery of large RNA molecules to target tissues, including the liver, muscle, heart, kidney, and brain. The SPT platform utilizes chemically modified plant secondary metabolites (glycosylated triterpenoids) to selectively enhance receptor-targeted delivery to endosomes and enable pH-driven endosomal release of the therapeutic. By improving the efficiency of intracellular delivery, Sapreme aims to create more effective treatment options for patients with genetically driven diseases. The technology remains inactive in circulation due to endosomal targeting and proprietary linker technology, resulting in improved tolerability.
Target Audience
The primary target audience includes patients with genetically driven diseases, as well as pharmaceutical and biotech companies seeking to co-develop RNA therapeutics.
Features
- Proprietary SPT platform based on chemically modified glycosylated triterpenoids
- Enhanced endosomal escape of large RNA molecules
- Receptor-targeted delivery to specific tissues
- pH-driven release of therapeutics from endosomes
- Improved tolerability due to inactivity in circulation
- Demonstrated proof-of-concept in rodents and non-human primates